MCID: VGN017
MIFTS: 47

Vaginal Cancer malady

Categories: Rare diseases, Cancer diseases, Reproductive diseases

Aliases & Classifications for Vaginal Cancer

Aliases & Descriptions for Vaginal Cancer:

Name: Vaginal Cancer 12 50 41 14
Vaginal Carcinoma 56 29
Vaginal Neoplasms 42 69
Vaginal Malignant Epithelial Tumor 56
Malignant Neoplasm of Vagina 12
Malignant Vaginal Neoplasm 69
Malignant Tumor of Vagina 12
Malignant Vaginal Tumor 12
Neoplasm of Vagina 12
Vaginal Neoplasia 69
Vagina Carcinoma 69
Vagina Neoplasm 12
Vaginal Tumor 12

Classifications:



External Ids:

Disease Ontology 12 DOID:119
ICD10 33 C52
ICD9CM 35 184.0
MeSH 42 D014625
NCIt 47 C3437 C7410
Orphanet 56 ORPHA180247
UMLS via Orphanet 70 C0262659
ICD10 via Orphanet 34 C52

Summaries for Vaginal Cancer

MedlinePlus : 41 vaginal cancer is a rare type of cancer. it is more common in women 60 and older. you are also more likely to get it if you have had a human papillomavirus (hpv) infection or if your mother took diethylstilbestrol (des) when she was pregnant. doctors prescribed des in the 1950's to prevent miscarriages. you are also at higher risk if you have had abnormal cells in the vagina, cervix, or uterus. it often doesn't have early symptoms. however, see your doctor if you notice bleeding that is not your period a vaginal lump pelvic pain a pap test can find abnormal cells that may be cancer. vaginal cancer can often be cured in its early stages. treatment might include surgery, radiation therapy, and chemotherapy. nih: national cancer institute

MalaCards based summary : Vaginal Cancer, also known as vaginal carcinoma, is related to vaginal disease and vaginitis, and has symptoms including pelvic pain and vaginal pruritus. An important gene associated with Vaginal Cancer is HLA-G (Major Histocompatibility Complex, Class I, G). The drugs Gardasil and Progesterone have been mentioned in the context of this disorder. Affiliated tissues include cervix, uterus and testes, and related phenotype is Decreased viability.

Disease Ontology : 12 A female reproductive system cancer that is located in the vagina.

Wikipedia : 71 Vaginal cancer is any type of cancer that forms in the tissues of the vagina. Primary vaginal cancer is... more...

Related Diseases for Vaginal Cancer

Diseases in the Vaginal Cancer family:

Vaginal Benign Neoplasm

Diseases related to Vaginal Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 14)
id Related Disease Score Top Affiliating Genes
1 vaginal disease 10.8
2 vaginitis 10.6
3 cervicitis 10.1
4 chronic rheumatic pericarditis 10.1 HLA-G SLC10A2
5 vaginal germ cell malignant tumor 9.9
6 vulvovaginal rhabdomyosarcoma 9.9
7 squamous cell carcinoma 9.7
8 cervical intraepithelial neoplasia 9.7
9 vulvar intraepithelial neoplasia 9.7
10 mayer-rokitansky-kuster-hauser syndrome 9.5
11 thrombosis 9.5
12 urethritis 9.5
13 chronic graft versus host disease 9.5
14 gastroparesis 8.7 EIF4A3 HLA-G HPD MAPK8IP1 MYLK2 PRDX2

Comorbidity relations with Vaginal Cancer via Phenotypic Disease Network (PDN):


Acute Cystitis Cervical Cancer, Somatic
Deficiency Anemia Vulva Cancer

Graphical network of the top 20 diseases related to Vaginal Cancer:



Diseases related to Vaginal Cancer

Symptoms & Phenotypes for Vaginal Cancer

UMLS symptoms related to Vaginal Cancer:


pelvic pain, vaginal pruritus

GenomeRNAi Phenotypes related to Vaginal Cancer according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00173-A 9.76 MYLK2 MAPK8IP1
2 Decreased viability GR00221-A-1 9.76 MYLK2
3 Decreased viability GR00221-A-2 9.76 MYLK2
4 Decreased viability GR00221-A-4 9.76 MAPK8IP1 MYLK2
5 Decreased viability GR00301-A 9.76 MAPK8IP1
6 Decreased viability GR00342-S-3 9.76 MAPK8IP1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-108 9.44 EIF4A3
8 Increased shRNA abundance (Z-score > 2) GR00366-A-133 9.44 EIF4A3
9 Increased shRNA abundance (Z-score > 2) GR00366-A-151 9.44 SLC10A2
10 Increased shRNA abundance (Z-score > 2) GR00366-A-189 9.44 SLC10A2
11 Increased shRNA abundance (Z-score > 2) GR00366-A-36 9.44 EIF4A3
12 Increased shRNA abundance (Z-score > 2) GR00366-A-4 9.44 EIF4A3
13 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.44 EIF4A3
14 Increased shRNA abundance (Z-score > 2) GR00366-A-45 9.44 SLC10A2
15 Increased shRNA abundance (Z-score > 2) GR00366-A-57 9.44 EIF4A3
16 Increased shRNA abundance (Z-score > 2) GR00366-A-6 9.44 EIF4A3 SLC10A2
17 Increased shRNA abundance (Z-score > 2) GR00366-A-81 9.44 SLC10A2
18 Increased shRNA abundance (Z-score > 2) GR00366-A-90 9.44 SLC10A2
19 Increased Nanog expression GR00371-A-3 9.13 EIF4A3
20 Increased Nanog expression GR00371-A-4 9.13 EIF4A3 MAPK8IP1

Drugs & Therapeutics for Vaginal Cancer

FDA approved drugs:

id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Gardasil 17 46 quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine Merck Approved June 2006

Drugs for Vaginal Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 307)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Progesterone Approved, Vet_approved Phase 4,Phase 3,Phase 2 57-83-0 5994
2
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3 50-28-2 5757 53477783
3
Goserelin Approved Phase 4,Phase 3 65807-02-5 47725 5311128
4
Desogestrel Approved Phase 4 54024-22-5 40973
5
Nandrolone decanoate Approved, Illicit Phase 4 360-70-3 9677
6
Nandrolone Approved, Experimental, Illicit Phase 4 434-22-0, 62-90-8 9904 229455
7
Norethindrone Approved Phase 4,Phase 2 68-22-4 6230
8 Dienogest Approved Phase 4 65928-58-7
9
Metformin Approved Phase 4,Phase 3 657-24-9 14219 4091
10
Leuprolide Approved, Investigational Phase 4 53714-56-0 3911 657181
11
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
12
Menotropins Approved Phase 4 61489-71-2 5360545
13
Loperamide Approved Phase 4,Phase 2 53179-11-6 3955
14
Glycerol Approved, Experimental Phase 4 56-81-5 753
15 silver nitrate Phase 4
16 Progestins Phase 4,Phase 2,Phase 3
17 Estradiol valerate Phase 4,Phase 2,Phase 3 979-32-8
18 Contraceptive Agents Phase 4,Phase 3,Phase 2
19 Contraceptive Agents, Male Phase 4,Phase 3,Phase 2
20 Contraceptives, Oral Phase 4,Phase 3,Phase 2
21 Anabolic Agents Phase 4,Phase 2,Phase 1,Early Phase 1
22 Norethindrone acetate Phase 4,Phase 2
23 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
24 Androgens Phase 4,Phase 2,Phase 1,Early Phase 1
25 Anesthetics Phase 4,Phase 3,Phase 2
26 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
27 Vaccines Phase 4,Phase 3,Phase 2,Phase 1
28 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
29 Estradiol 17 beta-cypionate Phase 4,Phase 2,Phase 3
30 Estradiol 3-benzoate Phase 4,Phase 2,Phase 3
31 Estrogens Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
32 Polyestradiol phosphate Phase 4,Phase 2,Phase 3
33 Anti-Infective Agents Phase 4,Phase 2,Phase 3,Phase 1
34 Anti-Infective Agents, Local Phase 4
35 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1
36 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
37
Lactitol Phase 4 585-86-4 3871
38 Chorionic Gonadotropin Phase 4,Phase 2
39 Follicle Stimulating Hormone Phase 4
40 Gastrointestinal Agents Phase 4,Phase 3,Phase 2
41 Norethindrone acetate, ethinyl estradiol, ferrous fumarate drug combination Phase 4
42 Norinyl Phase 4
43 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2
44 Hypoglycemic Agents Phase 4
45 Fertility Agents Phase 4,Phase 3,Phase 2
46 Contraceptives, Oral, Combined Phase 4
47 Tin Fluorides Phase 4
48 Dacuronium Phase 4
49 Antidiarrheals Phase 4,Phase 2
50 Laxatives Phase 4,Phase 2

Interventional clinical trials:

(show top 50) (show all 388)
id Name Status NCT ID Phase
1 Upper Vaginectomy Versus Brachytherapy in Patients With Early Stage Endometrial Cancer Treated With Laparoscopic Surgery Unknown status NCT00719017 Phase 4
2 Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls? Unknown status NCT01101750 Phase 4
3 The Treatment of Bartholin´s Cyst or Abscess With Silver Nitrate Unknown status NCT00786461 Phase 4
4 Study of the Efficacy of Dienogest in the Treatment of Uterine Leiomyomas When Compared to Desogestrel and Goserelin Unknown status NCT01738724 Phase 4
5 Comparing the Rate of Insufficient Cells for Diagnosis Between Surepath® and Conventional Smear in Women After Radiation Therapy for Cervical Cancer Completed NCT01988376 Phase 4
6 Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects Completed NCT00947115 Phase 4
7 Reactogenicity Study of Cervarix and Gardasil in UK Adolescent Girls Completed NCT00956553 Phase 4
8 Evaluation of Physiologic and Standard Sex Steroid Replacement Regimens in Women With Premature Ovarian Failure Completed NCT00732693 Phase 4
9 Menopur® Versus Follistim® in Polycystic Ovarian Syndrome (PCOS) Completed NCT00805935 Phase 4
10 TOMUS-Trial Of Mid-Urethral Slings Completed NCT00325039 Phase 4
11 Randomized Controlled Trial (RCT)Comparing GYNAECARE MORCELLEX Versus ROTOCUT GI Tissue Morcellators Completed NCT00743080 Phase 4
12 Metformin and Oral Contraceptives in PCOS Completed NCT00451568 Phase 4
13 Transmission Reduction and Prevention With HPV Vaccination (TRAP-HPV) Study Recruiting NCT01824537 Phase 4
14 Contraceptive Pill and Hormonal Vaginal Ring in Women With Polycystic Ovary Syndrome Recruiting NCT01588873 Phase 4
15 Surgical Success After Laparoscopic vs Abdominal Hysterectomy Recruiting NCT01793584 Phase 4
16 The Vaginal Health Trial Active, not recruiting NCT02516202 Phase 4
17 The Efficacy of Tachosil® for Prevention of Hemorrhage After Loop Electrosurgical Excisional Procedure (LEEP) Active, not recruiting NCT02629510 Phase 4
18 Scientific Evaluation of One or Two Doses of the Bivalent or Nonavalent Prophylactic HPV Vaccines Not yet recruiting NCT03180034 Phase 4
19 Study of the Elevate Apical and Posterior Prolapse Repair System Compared to Native Tissue Repair for Pelvic Organ Prolapse Terminated NCT02123992 Phase 4
20 Effect of Cetrorelex Acetate on Ovarian Function in Women Undergoing Chemotherapy Withdrawn NCT00507780 Phase 4
21 Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer Unknown status NCT01087268 Phase 3
22 Randomized Trial of Vaginal Self Sampling for Human Papillomavirus (HPV) Unknown status NCT01095198 Phase 2, Phase 3
23 Saginil in vs. Placebo for Gynecologic Oncology Patients Affected by Vaginitis Unknown status NCT01420510 Phase 2, Phase 3
24 Cognitive Behavioral Therapy (CBT) and Physical Exercise for Climacteric Symptoms in Breast Cancer Patients Experiencing Treatment-Induced Menopause: a Multicenter Randomized Trial Unknown status NCT00582244 Phase 3
25 Single-port Access Laparoscopic-assisted Vaginal Hysterectomy Unknown status NCT01048931 Phase 3
26 The Efficacy and Safety of the Postoperative Adjuvant Treatment in Patients With High-risk Stage I Endometrial Carcinoma Unknown status NCT01820858 Phase 3
27 The IMAP Study Improving Management of Mildly Abnormal Pap Smears Unknown status NCT00119509 Phase 3
28 Two-dose Schedule of Quadrivalent HPV Recombinant Vaccine in 11-year-old Boys in Mexico City Unknown status NCT02382900 Phase 3
29 Influence of Aromatase Inhibitors and GnRH Analogs to Treat Uterine Leiomyoma by Vaginal Hysterectomy Unknown status NCT01280045 Phase 3
30 Trial of Male Circumcision: HIV, Sexually Transmitted Disease (STD) and Behavioral Effects in Men, Women and the Community Unknown status NCT00124878 Phase 3
31 Pelvic Drains After Radical Hysterectomy in Treating Patients With Uterine, Cervical, or Vaginal Cancer Completed NCT00003267 Phase 3
32 Cervical Intraepithelial Neoplasm (CIN)-Warts Efficacy Trial in Women (Gardasil)(V501-013)(COMPLETED) Completed NCT00092521 Phase 3
33 A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006) Completed NCT01047345 Phase 3
34 Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001) Completed NCT00543543 Phase 3
35 A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501, qHPV) in Mid-Adult Women (V501-019) Completed NCT00090220 Phase 3
36 Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis Completed NCT00033605 Phase 3
37 GARDASIL™ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046) Completed NCT01245764 Phase 3
38 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
39 Impact of Lactate-Containing Vaginal Lubricant on Sexual Dysfunction in Young Breast Cancer Survivors Completed NCT00981305 Phase 3
40 Efficacy and Safety of Clino-san on Vaginal Dryness of Breast Cancer Patients Completed NCT00607295 Phase 3
41 Pilocarpine in Treating Vaginal Dryness in Patients With Breast Cancer Completed NCT00343382 Phase 3
42 External-Beam Radiation Therapy Compared With Vaginal Brachytherapy After Surgery for Stage I Endometrial Cancer Completed NCT00376844 Phase 3
43 Hormone Replacement Therapy for Hot Flashes and/or Vaginal Symptoms in Postmenopausal Women Receiving Tamoxifen for Breast Cancer Completed NCT00026286 Phase 3
44 Laparoscopic Surgery or Standard Surgery in Treating Patients With Endometrial Cancer or Cancer of the Uterus Completed NCT00002706 Phase 3
45 Self-sampling and Human Papillomavirus (HPV)-Testing for Unscreened Women in Cervical Cancer Prevention Completed NCT01014026 Phase 3
46 ITIC (Imiquimod Therapy in Cervical Intraepithelial Neoplasia)-Trial Completed NCT00941252 Phase 2, Phase 3
47 Laparoscopic vs Abdominal Radical Hysterectomy In Patients With Early Cervical Cancer Completed NCT01258413 Phase 3
48 Tension-free Vaginal Tape (TVT) Versus Bulking Agent for the Treatment of Post Vulvectomy Urinary Incontinence Completed NCT01148290 Phase 3
49 Hyperthermia Combined Brachytherapy in CCU Completed NCT01474356 Phase 3
50 A Phase III Randomized Trial of Topical Vaginal Fluorouracil (5-Fluorouracil, 5-FU) Maintenance Therapy Versus Observation After Standard Treatment for High-Grade Cervical Dysplasia in HIV-Infected Women Completed NCT00000758 Phase 3

Search NIH Clinical Center for Vaginal Cancer

Cochrane evidence based reviews: vaginal neoplasms

Genetic Tests for Vaginal Cancer

Genetic tests related to Vaginal Cancer:

id Genetic test Affiliating Genes
1 Vaginal Neoplasm 29

Anatomical Context for Vaginal Cancer

MalaCards organs/tissues related to Vaginal Cancer:

39
Cervix, Uterus, Testes, Liver, Breast, Lymph Node

The Foundational Model of Anatomy Ontology organs/tissues related to Vaginal Cancer:

18
The Vagina

Publications for Vaginal Cancer

Articles related to Vaginal Cancer:

(show top 50) (show all 127)
id Title Authors Year
1
Radical Hysterectomy and Total Abdominal Vaginectomy for Primary Vaginal Cancer. ( 26825828 )
2016
2
Definitive treatment of primary vaginal cancer with radiotherapy: multi-institutional retrospective study of the Korean Radiation Oncology Group (KROG 12-09). ( 26768782 )
2016
3
Vaginal cancer possibly caused by pessary and immunocompromised condition: Multiple risk factors may influence vaginal cancer development. ( 26914159 )
2016
4
Brachytherapy improves survival in primary vaginal cancer. ( 27036631 )
2016
5
Prognostic Factors in Primary Vaginal Cancer: A Single Institute Experience and Review of Literature. ( 27486283 )
2016
6
Breast metastasis from vaginal cancer. ( 27444140 )
2016
7
High-grade vaginal intraepithelial neoplasia and risk of progression to vaginal cancer: a multicentre study of the Italian Society of Colposcopy and Cervico-Vaginal Pathology (SICPCV). ( 27010135 )
2016
8
Outcomes with image-based interstitial brachytherapy for vaginal cancer. ( 27321150 )
2016
9
Prognostic impact of clinical tumor size on overall survival for subclassifying stages I and II vaginal cancer: A SEER analysis. ( 26970567 )
2016
10
Vulvar and Vaginal Cancer, Vulvar Intraepithelial Neoplasia 3 and Vaginal Intraepithelial Neoplasia 3: Experience of a Referral Institute. ( 27430086 )
2016
11
Role of Radical Surgery in Early Stages of Vaginal Cancer-Our Experience. ( 27327154 )
2016
12
The impact of FDG-PET/CT in the management of patients with vulvar and vaginal cancer. ( 26790773 )
2016
13
Treatment of early stage vaginal cancer with EBRT and MRI-based intracavitary brachytherapy: A retrospective case review. ( 27536721 )
2016
14
PROGNOSTIC SIGNIFICANCE OF TUMOR SIZE IN SQUAMOUS CELL CARCINOMA OF THE VULVA: IGCS-0107 Vulvar and Vaginal Cancer. ( 25955951 )
2015
15
Primary vaginal cancer: role of MRI in diagnosis, staging and treatment. ( 25966291 )
2015
16
Vaginal Intraepithelial Neoplasia: Histopathological Upgrading of Lesions and Evidence of Occult Vaginal Cancer. ( 26461231 )
2015
17
Vulval and vaginal cancer in pregnancy. ( 26526939 )
2015
18
Staging for vaginal cancer. ( 25847318 )
2015
19
LASER VAPORIZATION IN VULVAR INTRAEPITHELIAL NEOPLASIA (VIN), VAGINAL INTRAEPITHELIAL NEOPLASIA (VAIN) AND CONDYLOMATA ACUMINATA: IGCS-0093 Vulvar and Vaginal Cancer. ( 25955950 )
2015
20
Patterns of care and brachytherapy boost utilization for vaginal cancer in the United States. ( 25413431 )
2015
21
Definitive radiotherapy for primary vaginal cancer: correlation between treatment patterns and recurrence rate. ( 25614068 )
2015
22
Sarcoid-like reaction mimicking vaginal cancer recurrence. ( 26420533 )
2015
23
Image-based multichannel vaginal cylinder brachytherapy for vaginal cancer. ( 25456026 )
2015
24
Management of Vaginal Cancer. ( 26411952 )
2015
25
Adoption and impact of concurrent chemoradiation therapy for vaginal cancer: A National Cancer Data Base (NCDB) study. ( 25281493 )
2014
26
Successful pregnancy after uterus-sparing chemoradiation therapy for vaginal cancer. ( 25432539 )
2014
27
Effect of ageing on cervical or vaginal cancer in Swedish women previously treated for cervical intraepithelial neoplasia grade 3: population based cohort study of long term incidence and mortality. ( 24423603 )
2014
28
Vaginal cancer in a patient with complicated prolapse history: a case report. ( 25181382 )
2014
29
Improved survival in p16-positive vaginal cancers across all tumor stages but no correlation with MIB-1. ( 25319982 )
2014
30
HDR brachytherapy for the reirradiation of cervical and vaginal cancer: Analysis of efficacy and dosage delivered to organs at risk. ( 24161366 )
2014
31
Human papillomavirus genotype prevalence in invasive vaginal cancer from a registry-based population. ( 24785610 )
2014
32
Targeting human papillomavirus to reduce the burden of cervical, vulvar and vaginal cancer and pre-invasive neoplasia: establishing the baseline for surveillance. ( 24505474 )
2014
33
Uterine prolapse complicated by vaginal cancer: a case report and literature review. ( 24481208 )
2014
34
Prognostic factors for curative pelvic exenterations in patients with recurrent uterine cervical or vaginal cancer. ( 25254565 )
2014
35
Vaginal cancer with multiple liver and pulmonary metastases that achieved long-term survival. ( 24396823 )
2013
36
Is there a place for sentinel technique in treatment of vaginal cancer?: feasibility, clinical experience, and results. ( 24177255 )
2013
37
Does histologic type correlate to outcome after pelvic exenteration for cervical and vaginal cancer? ( 23212765 )
2013
38
Urethral dosimetry and toxicity with high-dose-rate interstitial brachytherapy for vaginal cancer. ( 23453679 )
2013
39
Vaginal cancer: the experience from 2 large academic centers during a 15-year period. ( 23609592 )
2013
40
HLA-G 3'UTR polymorphisms in high grade and invasive cervico-vaginal cancer. ( 23228396 )
2013
41
A case of vaginal cancer with uterine prolapse. ( 25371880 )
2013
42
Dosimetric comparison of multichannel with one single-channel vaginal cylinder for vaginal cancer treatments with high-dose-rate brachytherapy. ( 24080298 )
2013
43
Concurrent chemoradiation for vaginal cancer. ( 23762284 )
2013
44
Acr appropriateness Criteria management of vaginal cancer. ( 24575547 )
2013
45
Treatment of locally advanced vaginal cancer with radiochemotherapy and magnetic resonance image-guided adaptive brachytherapy: dose-volume parameters and first clinical results. ( 21868174 )
2012
46
American Brachytherapy Society consensus guidelines for interstitial brachytherapy for vaginal cancer. ( 22265440 )
2012
47
Vaginal cancer following etoposide-containing chemotherapy for metastatic gestational trophoblastic tumour. ( 22296447 )
2012
48
Vaginal cancer. ( 21571543 )
2012
49
Estimation of the optimal brachytherapy utilisation rate in the treatment of vaginal cancer and comparison with patterns of care. ( 22883660 )
2012
50
Therapeutic Mechanisms of Treatment in Cervical and Vaginal Cancer. ( 22943045 )
2012

Variations for Vaginal Cancer

Cosmic variations for Vaginal Cancer:

9 (show top 50) (show all 53)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM43896 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.818G>C p.R273P 5
2 COSM10725 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.701A>G p.Y234C 5
3 COSM10648 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.524G>A p.R175H 5
4 COSM44029 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.550G>A p.D184N 5
5 COSM45507 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.806G>C p.S269T 5
6 COSM10889 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.536A>G p.H179R 5
7 COSM10705 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.586C>T p.R196* 5
8 COSM10659 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.817C>T p.R273C 5
9 COSM11356 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.726C>G p.C242W 5
10 COSM46185 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.775G>C p.D259H 5
11 COSM45259 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.301A>T p.K101* 5
12 COSM43662 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.868C>A p.R290S 5
13 COSM10749 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.830G>T p.C277F 5
14 COSM11483 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.848G>A p.R283H 5
15 COSM10662 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.743G>A p.R248Q 5
16 COSM43624 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.875A>G p.K292R 5
17 COSM43660 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.719G>T p.S240I 5
18 COSM43878 TP53 cervix,NS,carcinoma,squamous cell carcinoma c.427G>A p.V143M 5
19 COSM29464 STK11 cervix,NS,carcinoma,squamous cell carcinoma c.169G>T p.E57* 5
20 COSM29465 STK11 cervix,NS,carcinoma,squamous cell carcinoma c.320A>G p.H107R 5
21 COSM3734673 STK11 cervix,NS,carcinoma,squamous cell carcinoma c.597G>C p.E199D 5
22 COSM25844 STK11 cervix,NS,carcinoma,squamous cell carcinoma c.647C>T p.S216F 5
23 COSM5089 PTEN cervix,NS,carcinoma,squamous cell carcinoma c.517C>T p.R173C 5
24 COSM763 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.1633G>A p.E545K 5
25 COSM12459 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.1637A>G p.Q546R 5
26 COSM773 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.3129G>T p.M1043I 5
27 COSM760 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.1624G>A p.E542K 5
28 COSM775 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.3140A>G p.H1047R 5
29 COSM12458 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.1634A>C p.E545A 5
30 COSM17442 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.1624G>C p.E542Q 5
31 COSM766 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.1636C>A p.Q546K 5
32 COSM1168056 PIK3CA cervix,NS,carcinoma,squamous cell carcinoma c.3145G>T p.G1049C 5
33 COSM580 NRAS cervix,NS,carcinoma,squamous cell carcinoma c.181C>A p.Q61K 5
34 COSM120958 NFE2L2 cervix,NS,carcinoma,squamous cell carcinoma c.235G>C p.E79Q 5
35 COSM518 KRAS cervix,NS,carcinoma,squamous cell carcinoma c.34G>C p.G12R 5
36 COSM552 KRAS cervix,NS,carcinoma,squamous cell carcinoma c.182A>G p.Q61R 5
37 COSM551 KRAS cervix,NS,carcinoma,squamous cell carcinoma c.182A>C p.Q61P 5
38 COSM555 KRAS cervix,NS,carcinoma,squamous cell carcinoma c.183A>T p.Q61H 5
39 COSM517 KRAS cervix,NS,carcinoma,squamous cell carcinoma c.34G>A p.G12S 5
40 COSM521 KRAS cervix,NS,carcinoma,squamous cell carcinoma c.35G>A p.G12D 5
41 COSM499 HRAS cervix,NS,carcinoma,squamous cell carcinoma c.182A>G p.Q61R 5
42 COSM483 HRAS cervix,NS,carcinoma,squamous cell carcinoma c.35G>T p.G12V 5
43 COSM480 HRAS cervix,NS,carcinoma,squamous cell carcinoma c.34G>A p.G12S 5
44 COSM497 HRAS cervix,NS,carcinoma,squamous cell carcinoma c.181C>G p.Q61E 5
45 COSM715 FGFR3 cervix,NS,carcinoma,squamous cell carcinoma c.746C>G p.S249C 5
46 COSM49175 FGFR2 cervix,NS,carcinoma,squamous cell carcinoma c.1976A>T p.K659M 5
47 COSM49174 FGFR2 cervix,NS,carcinoma,squamous cell carcinoma c.289G>A p.A97T 5
48 COSM5731 CTNNB1 cervix,NS,carcinoma,squamous cell carcinoma c.113G>C p.G38A 5
49 COSM5662 CTNNB1 cervix,NS,carcinoma,squamous cell carcinoma c.110C>T p.S37F 5
50 COSM5730 CTNNB1 cervix,NS,carcinoma,squamous cell carcinoma c.122C>A p.T41N 5

Expression for Vaginal Cancer

Search GEO for disease gene expression data for Vaginal Cancer.

Pathways for Vaginal Cancer

GO Terms for Vaginal Cancer

Cellular components related to Vaginal Cancer according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 Golgi membrane GO:0000139 8.8 HLA-G HPD RAB2A

Sources for Vaginal Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....